The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients

被引:25
作者
Barnes, DM [1 ]
Millis, RR
Gillett, CE
Ryder, K
Skilton, D
Fentiman, IS
Rubens, RD
机构
[1] Guys Hosp, Hedley Atkins Canc Res UK Breast Pathol Lab, London SE1 9RT, England
[2] Guys Hosp, Canc Res UK Clin Oncol Data Unit, London SE1 9RT, England
[3] Guys Hosp, Clin Oncol Unit, London SE1 9RT, England
关键词
D O I
10.1677/erc.0.0110085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The oestrogen receptor (ER) status of 2660 patients with primary breast cancer has been related to the effect of different adjuvant systemic therapies on survival. However, as patients in the various treatment groups also had different prognostic features comparison between treatments was difficult. Over 90% of patients receiving tamoxifen (Tam) were postmenopausal compared with <20% of those receiving chemotherapy (CT). The latter had more positive nodes (85% vs 54%) and grade III tumours (54% vs 30%) than the Tam group. The combined CT and Tam group had similar characteristics to the CT alone group. The current reported increase in the proportion of women with ER+ tumours is explained by immunohistochemical analysis of ER and screening programmes. ER status was unrelated to survival in patients with small, low grade, node-negative tumours which was no different from that expected for age-matched women taken from the general population. The value of adjuvant treatment in these patients is therefore questionable. In those given any adjuvant treatment, survival of women with ER+ tumours was prolonged, with the greatest effect being seen in those receiving Tam. Patients with ER- tumours benefited from CT but the addition of Tam to CT improved survival only in those with ER+ tumours. ER status is now established as a major predictive factor for treatment selection in primary disease. Studies of prognostic and predictive markers may be invalidated by use of adjuvant therapy and selection criteria for different treatments. Survival will be influenced by both tumour biology and therapy. This important consideration must be remembered when analysing new markers, particularly in small studies.
引用
收藏
页码:85 / 96
页数:12
相关论文
共 22 条
  • [1] Abe O, 1998, LANCET, V352, P930
  • [2] ALSAATI T, 1993, INT J CANCER, V55, P651
  • [3] Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
    Barnes, DM
    Harris, WH
    Smith, P
    Millis, RR
    Rubens, RD
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (09) : 1445 - 1451
  • [4] Oestrogen and progesterone receptors in breast cancer: past, present and future
    Barnes, DM
    Hanby, AM
    [J]. HISTOPATHOLOGY, 2001, 38 (03) : 271 - 274
  • [5] BAUM M, 1985, LANCET, V1, P836
  • [6] SUDDEN FALL IN BREAST-CANCER DEATH RATES IN ENGLAND AND WALES
    BERAL, V
    HERMON, C
    REEVES, G
    PETO, R
    [J]. LANCET, 1995, 345 (8965): : 1642 - 1643
  • [7] ABC of breast diseases - Screening for breast cancer
    Blamey, RW
    Wilson, ARM
    Patnick, J
    [J]. BRITISH MEDICAL JOURNAL, 2000, 321 (7262) : 689 - 693
  • [8] Clarke M, 1998, LANCET, V351, P1451
  • [9] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP
    ELSTON, CW
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1991, 19 (05) : 403 - 410
  • [10] HOWELL A, 1984, LANCET, V2, P307